Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
Clinical Psychopharmacology and Neuroscience
; : 37-40, 2014.
Article
in En
| WPRIM
| ID: wpr-53119
Responsible library:
WPRO
ABSTRACT
OBJECTIVE: We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD). METHODS: Major depressive episode was diagnosed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) according to the DSM-IV text revision (DSM-IV-TR) criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Blood sampling and clinical evaluation were performed on days 0, 28, and 56. RESULTS: Duloxetine treatment for 8 weeks significantly increased the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels but not the homovanillic acid (HVA) levels in responders with MDD. CONCLUSION: These results imply that noradrenaline plays an important role in alleviating depressive symptoms.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Plasma
/
Norepinephrine
/
Brain-Derived Neurotrophic Factor
/
Diagnostic and Statistical Manual of Mental Disorders
/
Depression
/
Depressive Disorder, Major
/
Duloxetine Hydrochloride
/
Homovanillic Acid
Type of study:
Guideline
/
Qualitative_research
Limits:
Humans
Language:
En
Journal:
Clinical Psychopharmacology and Neuroscience
Year:
2014
Type:
Article